| abstract |
The present disclosure is directed to chimeric receptors that binds the Fc portion of human immunoglobulin and delivers activation signals. The chimeric receptor of the present disclosure may comprise an extracellular ligand-binding domain of F158 FCGR3A or the high-affinity V158 FCGR3A variant, the hinge and transmembrane domains of CD8α, and the signaling domains of CD3ζ and 4-1BB. The chimeric receptor of the present disclosure has a high affinity for Rituximab, Trastuzumab, hu14.18K322A, and other therapeutic antibodies, making it useful for augmenting the efficacy of antibody therapy against various cancers. |